Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry.

[1]  Nancy A Dreyer,et al.  Registries for robust evidence. , 2009, JAMA.

[2]  A. Dirksen,et al.  Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency , 2009, Respiratory research.

[3]  R. Stockley,et al.  Rate of progression of lung function impairment in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[4]  A. Dirksen,et al.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[5]  M. Rahalkar,et al.  Chest , 2009, Indian Journal of Radiology and Imaging.

[6]  M. Miravitlles,et al.  Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency , 2008, Therapeutic advances in respiratory disease.

[7]  M. Miravitlles,et al.  Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency , 2007, International journal of chronic obstructive pulmonary disease.

[8]  R. Stockley.  Biomarkers in COPD: time for a deep breath , 2007, Thorax.

[9]  R. Stockley,et al.  Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development , 2007, European Respiratory Journal.

[10]  R. Vidal,et al.  Diagnóstico y tratamiento del déficit de alfa-1-antitripsina , 2006 .

[11]  M. Miravitlles,et al.  Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics , 2006, Thorax.

[12]  Jan Stolk,et al.  Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. , 2004, American journal of respiratory and critical care medicine.

[13]  M. Miravitlles,et al.  Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. , 2003, Chest.

[14]  D. Lomas,et al.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. , 2002, The Journal of clinical investigation.

[15]  R. Stockley,et al.  The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. , 2002, American journal of respiratory and critical care medicine.

[16]  R. Stockley,et al.  Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. , 2001, American journal of respiratory and critical care medicine.

[17]  N. Konietzko,et al.  Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. , 2001, Chest.

[18]  L. Fleming,et al.  Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. , 2000, Chest.

[19]  E. Piitulainen,et al.  Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). , 1999, The European respiratory journal.

[20]  M. Miravitlles,et al.  Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. , 1998, Respiratory medicine.

[21]  J. Stoller.  Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. , 1997, Chest.

[22]  M. Schluchter,et al.  Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. , 1997, Chest.

[23]  N. Seersholm.  Body mass index and mortality in patients with severe alpha 1-antitrypsin deficiency. , 1997, Respiratory medicine.

[24]  M. Schluchter,et al.  A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods , 1994 .